A Passion for Science and a Commitment to Dermatology
Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients’ lives. The patient is at the heart of everything we do.
Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients’ lives. The patient is at the heart of everything we do.
Location: United States, California, Long Beach
Employees: 201-500
Total raised: $200M
Founded date: 2016
Investors 2
| Date | Name | Website |
| 06.11.2022 | Hercules C... | htgc.com |
| - | Roivant | roivant.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.06.2021 | - | $200M | - |
Mentions in press and media 2
| Date | Title | Description |
| 08.06.2021 | Dermavant Sciences Raises $200M in Funding | Dermavant Sciences, a Long Beach CA, Durham, NC, and Basel, Switzerland-based biopharmaceutical company which specializes in immunodermatology therapy, raised $200M in funding. In details, the company has entered into: a $160m revenue inter... |
| 11.03.2021 | Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference | LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar 11, 2021-- Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today ann... |